LULIBET CREAM
Out of Stock
Lulibet Cream 30gm, manufactured by Intas Pharmaceuticals Ltd., is a prescription-strength, topical antifungal cream formulated to address the specific challenge of dermatophytic and candidal fungal skin infections, among the most prevalent and persistently recurrent dermatological conditions encountered in clinical practice. Conditions such as ringworm (tinea corporis), athlete's foot (tinea pedis), and jock itch (tinea cruris) are caused by dermatophyte fungi that invade the superficial keratinised layers of the skin, producing the characteristic symptoms of redness, scaling, itching, cracking, and burning that significantly impair daily comfort and skin integrity. What distinguishes Lulibet Cream clinically is its active ingredient Luliconazole, a next-generation imidazole antifungal with a distinctively high binding affinity for fungal cytochrome P450 enzymes, enabling it to exert potent fungicidal activity at concentrations well below those required by earlier-generation azole antifungals. This superior potency translates into meaningful clinical outcomes, including a faster onset of visible improvement and shorter treatment durations. Lulibet Cream is for external topical use only and must be used under the guidance of a qualified dermatologist or medical professional. Animeal is proud to offer Lulibet Cream 30gm as part of our commitment to providing prescription-grade, dermatologist-recommended therapeutic products to support the skin health of every member of your family.
Ingredients:
Luliconazole 1% w/w: Luliconazole is a novel, enantiomerically pure imidazole antifungal agent with a distinct chemical structure that incorporates an imidazolylthio group, conferring exceptional potency and sustained skin retention compared to earlier azole antifungals such as clotrimazole, miconazole, and ketoconazole. Luliconazole exerts its primary antifungal action by inhibiting the fungal cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase (also known as CYP51 or Erg11). This enzyme is a critical component of the ergosterol biosynthesis pathway, which is the principal biochemical route by which fungi synthesise ergosterol, the structural sterol equivalent of cholesterol in mammalian cells. Ergosterol is essential for maintaining fungal cell membrane fluidity, selective permeability, and structural integrity. When lanosterol 14-alpha-demethylase is inhibited by Luliconazole, the conversion of lanosterol to ergosterol is blocked, resulting in the accumulation of toxic methylated sterol precursors, most notably 14-alpha-methylsterol intermediates, within the fungal cell membrane. This aberrant sterol accumulation disrupts the physical architecture and permeability of the fungal membrane, causing increased membrane porosity, leakage of intracellular contents including potassium ions, nucleotides, and amino acids, and ultimately fungal cell lysis and death. Unlike fungistatic azoles that merely inhibit fungal growth, Luliconazole achieves fungicidal concentrations against Trichophyton rubrum, Trichophyton mentagrophytes, and Candida spp. at clinically relevant doses, directly killing the organism rather than relying on the host immune system to clear residual fungi. Luliconazole also demonstrates a markedly prolonged skin retention profile, remaining at therapeutically active concentrations within the stratum corneum for up to 72 to 96 hours after a single application, which reduces the risk of treatment failure due to missed doses.
